We launched this series by setting out why biopharma looks compelling right now. This issue turns to the first name on our catalyst-driven watchlist: Arrowhead Pharmaceuticals (ARWR) — a company chasing one of the largest opportunities in cardiometabolic medicine, and one that has just cleared its most important hurdle, with pivotal Phase 3 data in severe hypertriglyceridemia reading out positively in late July.
Why we are watching Arrowhead
Arrowhead is a leader in RNA interference (RNAi) — medicines that silence disease-causing genes — built on a delivery platform that lets it address a broad pipeline across cardiometabolic disease, obesity, pulmonary and other areas. It has already crossed the line from clinical-stage to commercial: plozasiran (REDEMPLO®) was approved for the ultra rare disease, familial chylomicronemia syndrome in late 2025. The investment question now is whether Arrowhead can expand that first approval into a far larger market — and that question gets answered by a cluster of anticipated events this year.
The central catalyst: plozasiran in severe hypertriglyceridemia
The most important event on Arrowhead's near-term calendar has now resolved — positively. On July 22, 2026, the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in severe hypertriglyceridemia (sHTG) both met their primary endpoint and all prespecified secondary endpoints, with median triglyceride reductions of 79% and 81% respectively at month 12, versus about 27% on placebo. Just as important for a disease defined by its danger, acute pancreatitis events fell by 78% across the broad study population — and by 100% in the highest-risk subgroup — with no new safety signals. The shares rose about 18% on the data. This takes plozasiran — already carrying FDA Breakthrough Therapy designation in sHTG — from ultra-rare FCS toward the multi-million-patient sHTG population that is the central driver of Arrowhead's revenue outlook. What remains near-term: topline data from the third study, MUIR-3, and the supplemental FDA filing the company still targets before year-end.
The Competitive Backdrop
Arrowhead is not alone in chasing severe hypertriglyceridemia. Ionis Pharmaceuticals' olezarsen (marketed as TRYNGOLZA), an antisense drug, targets the same market and recently secured an expanded FDA label in sHTG — a reminder that this is a real, contested opportunity rather than a onehorse race. When two independent technologies are converging on the same large market, it tells us the underlying prize is real; it also means head-to-head data will matter for market share. On the numbers so far, plozasiran's roughly 79–81% triglyceride reductions give Arrowhead a strong competitive hand, but the rivalry is something to watch: strong data for one program can read across, for better or worse, to the other.
The free option: obesity
Beyond sHTG, Arrowhead carries meaningful optionality in obesity, the most investor-sensitive theme of the GLP-1 era. Its earlier-stage RNAi programs (including ARO-INHBE and ARO-ALK7) target fat loss with preservation of muscle — a profile the market prizes as a potential complement to GLP-1 drugs — and a first combined-target cardiometabolic readout is expected in the second half of 2026. These are earlier and less certain than the sHTG program, but in the current environment even early obesity data can move the stock sharply, and they add partnering optionality on top of the core thesis.
How this fits our process — and the risks
Arrowhead fits our screen well: a de-risked mechanism (approved in FCS, and now supported by positive Phase 3 sHTG data) with additional, lower-probability upside layered on top. The risks remain real even after a strong readout. The MUIR-3 study and the regulatory review still lie ahead; approval and label language are not guaranteed; the sHTG market will be competitive, including against Ionis's olezarsen; the obesity data are early; and biotech concentration can produce severe losses, up to the entire amount invested. Note, too, that much of the good news from the SHASTA readout is now reflected in the share price after the move on the data.
How we are positioning
Our team is positioned in ARWR. With the SHASTA studies now read out, the events we are watching next are the detailed data presentation at the European Society of Cardiology Congress on August 30, the MUIR-3 topline, the supplemental FDA filing targeted before year-end, and the early launch trajectory in sHTG. As always, biopharma lends itself to defined-risk structures because the returns cluster around discrete, anticipated catalysts — but the specific entry levels, sizing and any options overlays we use are reserved for clients and are not published here. If you would like to understand how we are positioned around Arrowhead's calendar from here, your Serra Wealth advisor can walk you through it.
If you would like to discuss whether — and how much — biopharma exposure fits your portfolio and risk tolerance, your Serra Wealth advisor is the right first call.
Important disclosures
This newsletter is a marketing communication provided for information purposes only. It does not constitute investment advice, a personal recommendation, or an offer or solicitation to buy or sell any financial instrument. References to specific securities are illustrative only and are not recommendations; examples cited are not representative of all names followed, and other securities monitored did not perform comparably. Options are complex instruments and carry a high risk of rapid loss; certain strategies can result in losses exceeding the initial amount invested. Biotechnology securities are highly volatile and exposed to binary clinical and regulatory events. Simulated past performance and actual past performance are not reliable indicators of future performance. Investors should consider their objectives, financial situation and risk tolerance, and consult their Serra Wealth advisor, before acting on any information herein. Capital is at risk.